Century Therapeutics, Inc.
IPSCAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Mar 13, 2026 | Leerink Partners | Daina Graybosch | $2.00(-21%) | $2.52 | StreetInsider |
| Jan 20, 2026 | Piper Sandler | $4.00(+84%) | $2.17 | TheFly | |
| Nov 6, 2024 | H.C. Wainwright | Mitchell Kapoor | $5.00(+260%) | $1.39 | StreetInsider |
| Apr 12, 2024 | Piper Sandler | Edward Tenthoff | $9.00(+122%) | $4.05 | StreetInsider |
| Jan 5, 2023 | Piper Sandler | Edward Tenthoff | $14.00(+189%) | $4.84 | TheFly |
| Dec 27, 2022 | Chardan Capital | Geulah Livshits | $19.00(+235%) | $5.67 | TheFly |
| Nov 14, 2022 | H.C. Wainwright | $25.00(+127%) | $11.00 | Benzinga | |
| Apr 29, 2022 | Leerink Partners | $27.00(+124%) | $12.03 | Benzinga |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Apr 21, 2026 |
| Piper Sandler | maintain | Overweight | Jan 20, 2026 |
| Leerink Partners | downgrade | Outperform →Market Perform | Nov 17, 2025 |
| Chardan Capital | maintain | Buy | May 16, 2025 |
| HC Wainwright & Co. | maintain | Buy | Apr 3, 2025 |
| Guggenheim | maintain | Buy | Mar 28, 2025 |
| Chardan Capital | maintain | Buy | Mar 24, 2025 |
| Guggenheim | maintain | Buy | Mar 21, 2025 |
| Piper Sandler | maintain | Overweight | Mar 20, 2025 |
| Guggenheim | maintain | Buy | Jan 22, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jan 22, 2025 |
| Piper Sandler | maintain | Overweight | Dec 30, 2024 |
| Chardan Capital | maintain | Buy | Nov 7, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 6, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 15, 2024 |
| Piper Sandler | maintain | Overweight | Jun 17, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jun 4, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 10, 2024 |
| Piper Sandler | maintain | Overweight | Apr 12, 2024 |
| Canaccord Genuity | maintain | Buy | Mar 15, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 15, 2024 |
| HC Wainwright & Co. | maintain | Buy | Dec 7, 2023 |
| JP Morgan | downgrade | Overweight →Neutral | Aug 28, 2023 |
| Chardan Capital | maintain | Buy | Aug 10, 2023 |
| Piper Sandler | maintain | Overweight | Aug 10, 2023 |
Earnings History
Next report: Nov 12, 2026 · EPS est. $-0.12| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 12, 2026 | $-0.17 | $-0.11 | — | $2.2M |
| May 13, 2026 | $-0.11 | $-0.15 | — | $2.9M |
| Mar 12, 2026 | $-0.25 | $-0.28 | — | -$62.5K |
| Nov 13, 2025 | $-0.32 | $-0.39 | — | -$83.3K |
| Aug 14, 2025 | $-0.38 | $-0.38 | — | $25.0K |
| May 15, 2025 | $0.89 | $-0.31 | $109.2M | $41.3M |
| Mar 19, 2025 | $-0.43 | $-0.45 | $4.2M | $49.6M |
| Nov 5, 2024 | $-0.37 | $-0.46 | $791.0K | $440.0K |
News
PHILADELPHIA, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for type 1 diabetes (T1D) and other autoimmune diseases, today announced that the company will attend the upcoming 2026 Jefferies Global Healthcare Conference in London on November 18, 2026.
Century Therapeutics (NASDAQ: IPSC - Get Free Report) and BioStem Technologies (OTCMKTS:BSEM - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings. Analyst Ratings This is a breakdown of
Data demonstrated scalable production, in vivo function and immune evasion, and updated progress toward clinical dosing of CNTY-813, Century's iPSC-derived islet replacement therapy for type 1 diabetes
Century Therapeutics is rated a speculative Buy, with a $363M equity value and a focus on CNTY-813 for type 1 diabetes. IPSC's CNTY-813 aims to deliver insulin-producing islets without chronic systemic immunosuppression, leveraging Allo-Evasion 5.0 genetic edits. Strong preclinical results and a cash runway into Q1 2029 support the risk/reward, but lack of human data and potential dilution keep conviction low.
PHILADELPHIA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced the appointment of Joseph Truitt to its Board of Directors.
Completed pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy with functional cure potential in type 1 diabetes (T1D); IND submission on track for 4Q 2026 CNTY-813 preclinical data from oral presentation at ADA 2026 showed durable glucose control in vivo, immune evasion, and manufacturing success at clinical scale, advancing its potential as a functional cure for T1D Upcoming oral presentations at European Association for the Study of Diabetes (EASD 2026) and Bre…